Asli Bahar Ucar

Dr. Asli Bahar Ucar

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2025 in Anatolian Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
Emre KuduEmre Kudu
Emre Kudu
MAMustafa Altun
Mustafa Altun
Asli Bahar UcarAsli Bahar Ucar
Asli Bahar Ucar
CTCansu Tiriş
Cansu Tiriş
SKSinan Karacabey
Sinan Karacabey
AAArzu Denizbasi Altinok
Arzu Denizbasi Altinok
Aim: This study aims to identify key factors associated with 30-day emergency department (ED) revisits among patients discharged after upper gastrointestinal bleeding (UGIB), providing insights to optimize patient management and improve outcomes. Material and Methods: A single-center retrospective cohort study was conducted at a tertiary university hospital between January 1, 2018, and December 31, 2022. Adult patients (>18 years) diagnosed with UGIB were included, while those with incomplete data or transferred to other facilities were excluded. Data on demographics, clinical features, laboratory parameters, endoscopic findings, and revisits were analyzed. Univariate and multivariate logistic regression models were used to identify predictors of UGIB-related ED revisits. Results: Among 862 patients, the 30-day revisit rate was 19.9%, with 84 revisits related to UGIB. Female gender, malignancy, anticoagulant use, prior UGIB history, and lower discharge hemoglobin levels were identified as significant predictors of UGIB-related revisits. Patients with Forrest IA ulcers had a 42.9% revisit rate, while those with Forrest III ulcers showed a significantly lower rate of 5.5%. Erythrocyte suspension was used more frequently in the revisit group (83.3% vs. 61.2%, p<0.001), reflecting the severity of these cases. Conclusion: UGIB-related revisits are influenced by several factors, including anticoagulant use, malignancy, prior UGIB history, and endoscopic findings. Tailored discharge planning, patient education, and risk stratification are critical to reducing revisits. Future studies should focus on prospective validation and the development of predictive models for targeted interventions.

22 October 2025 in BMC Emergency Medicine
Verified
Journal Article
Open access
PDF file
Asli Bahar UcarAsli Bahar Ucar
Asli Bahar Ucar
HDHasan Demir
Hasan Demir
HAHaldun Akoglu
Haldun Akoglu
Background: Hydrazine is a volatile and highly toxic monopropellant used in the Emergency Power Unit (EPU) of F-16 aircraft. Although hydrazine is widely used in both military and industrial contexts, reports of its effects in non-occupational civilian populations are extremely limited. Acute civilian mass exposures are almost never systematically documented. On December 12, 2016, an F-16 crash in Diyarbakır, Türkiye, released hydrazine into an open-field setting, exposing unprotected civilians. This study aimed to characterize acute manifestations, evaluate associations with exposure duration and route, and identify operational implications. Methods: We conducted a retrospective descriptive study of 30 previously healthy male civilians exposed at the crash site. Clinical data, laboratory findings, ECGs, and imaging were retrieved from standardized emergency department records. Exposure duration—triangulated from patient interviews and operational logs—was analyzed as a continuous surrogate for dose, in line with Haber’s rule. Associations with symptom categories and exposure routes were assessed using nonparametric statistics, Fisher’s exact tests, and exploratory receiver operating characteristic (ROC) analysis. Results: Twenty patients (66.7%) developed symptoms, while ten remained asymptomatic. Symptom development correlated strongly with exposure duration (Spearman r = 0.61–0.68), with respiratory cases showing significantly longer exposures (median 45 vs. 14 min, p = 0.0017). Ophthalmologic findings (36.7%) were most frequent, while dermatologic (26.7%) and respiratory (13.3%) manifestations occurred exclusively in contact-exposed individuals ( p < 0.001 and p = 0.012, respectively). Inhalation-only exposure primarily caused ocular irritation. No patient exposed ≤ 5 min developed symptoms, whereas all symptomatic individuals reported longer exposures; ROC analysis supported discriminatory potential (AUC > 0.80), though results remain exploratory. A 26-year-old first responder developed acute hypoxemic respiratory failure after 45–60 min, recovering with supportive care. No hepatic, renal, neurologic, or cardiovascular complications occurred, and all patients were discharged within 24 h. Conclusions: This study provides one of the most extensive civilian datasets on acute hydrazine exposure. Findings highlight a strong dose–time relationship and route-specific patterns, with exposures > 5 min associated with clinically significant toxicity. While thresholds remain hypothesis-generating, all patients recovered rapidly with supportive care. Operational lessons include the need for rapid evacuation, immediate decontamination, and strict use of personal protective equipment, offering practical insights for toxicology practice and disaster preparedness.

25 August 2026 in Scottish Medical Journal
Verified
Journal Article
Closed access
CACanan Akman
Canan Akman
Asli Bahar UcarAsli Bahar Ucar
Asli Bahar Ucar
GYGokhan Yilmaz
Gokhan Yilmaz
AEAsim Bedri Erdem
Asim Bedri Erdem
MUMehmet Unaldi
Mehmet Unaldi
OKOzgur Karcioglu
Ozgur Karcioglu
Extracorporeal membrane oxygenation (ECMO) has a life-saving role in trauma management, with particular relevance to patients with acute respiratory failure. This narrative review describes the current evidence on the use of ECMO in the resuscitation of major trauma victims presenting with acute respiratory distress syndrome, cardiogenic shock, poisoning, burns, and traumatic brain injury, and highlights recent advances in the field. A comprehensive literature search of PubMed and EMBASE was performed for articles, using the MeSH/keywords. Over the past decade, ECMO has been increasingly applied for trauma management, encompassing both venovenous (VV) and venoarterial (VA) modes. VV-ECMO is primarily utilized in hypoxic respiratory failure following thoracic trauma and is associated with improved in-hospital mortality and higher discharge survival compared to conventional mechanical ventilation. VA-ECMO is reserved for hemodynamic collapse and extracorporeal cardiopulmonary resuscitation, a subset of VA-ECMO used specifically in cardiac arrest. Despite promising outcomes, challenges remain, including anticoagulation management, hemorrhagic complications, and the absence of trauma-specific prognostic models. Emerging applications include ECMO in traumatic brain injury, poisoning, and severe burns. Although ECMO improves outcomes in selected trauma patients, further high-quality studies are needed to define optimal selection criteria and to clarify its role across the spectrum of injuries.

21 August 2026 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CACanan Akman
Canan Akman
Asli Bahar UcarAsli Bahar Ucar
Asli Bahar Ucar
MGMehmet Can Girgin
Mehmet Can Girgin
BEBusra Erdem
Busra Erdem
GYGokhan Yilmaz
Gokhan Yilmaz
OKOzgur Karcioglu
Ozgur Karcioglu

29 September 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
CACanan Akman
Canan Akman
BEBusra Erdem
Busra Erdem
Asli Bahar UcarAsli Bahar Ucar
Asli Bahar Ucar
OIOzlem Inci
Ozlem Inci
MUMehmet Unaldi
Mehmet Unaldi
OKOzgur Karcioglu
Ozgur Karcioglu
Introduction/Objective: Immunosuppressed Patients (ISP) — defined by congenital or acquired deficiencies in systemic defense mechanisms — are disproportionately susceptible to viral respiratory infections. Agents such as SARS-CoV-2, Respiratory Syncytial Virus (RSV), influenza A and B, and Cytomegalovirus (CMV) cause significant morbidity in both immunocompetent and immunosuppressed individuals. Clinical manifestations range from mild influenza-like illness to severe pneumonia, respiratory failure, multiorgan dysfunction, and concurrent bacterial infections. Methods: A narrative synthesis of the literature was performed using Medline, CINAHL, Web of Science, and Scopus using relevant keywords ("immunosuppressed patients", "pneumonia", "lung infection", "antiviral", "cytomegalovirus", "influenza", "RSV") for publications between January 2000 and March 2026. Where available, Cochrane systematic reviews, meta-analyses, and high-quality randomised controlled trials were given precedence in the narrative synthesis; systematic review and meta-analytic procedures, including PRISMA guidelines, were not applied. Case reports, editorials, and opinion articles were excluded, other than a small number of case series describing rare therapeutic strategies for which no higher-level evidence was available. Evidence was collated narratively and presented in tabular format. Results: Although numerous antiviral compounds have been developed and studied, the optimal agent for managing severe viral infections in ISP remains uncertain. Empiric oseltamivir for influenza is typically initiated immediately upon clinical suspicion. Other antivirals — including ganciclovir for CMV, cidofovir for adenovirus, and ribavirin for RSV or parainfluenza — are generally reserved for confirmed or highly suspected infections in high-risk populations. The safety profile of each agent must be evaluated individually before initiating the treatment. Discussion: Direct-acting antivirals achieve faster virologic clearance but do not consistently reduce shortterm mortality in ISP. Antiviral selection requires integration of pathogen identity, timing of therapy, underlying immune deficit, and individual risk-benefit assessment. Novel agents and combination strategies warrant further investigation in this population. Conclusion: ISP with viral pneumonia represents a clinically complex, high-risk group requiring individualized treatment strategies, including antiviral agents, vigilant safety monitoring, and proactive preventive measures, especially vaccination. Virologic clearance benefits associated with direct-acting antivirals such as remdesivir do not consistently translate into a short-term mortality benefit, underscoring the need for outcome- specific interpretation of the evidence. A nuanced understanding of the available antiviral armamentarium is essential to optimise outcomes in this vulnerable population.

28 February 2025
Verified
Book
Open access
PDF file
OKOzgur Karcioglu
Ozgur Karcioglu
NSNeslihan Ergün Süzer
Neslihan Ergün Süzer
AÖAhmet Celal Özsoy
Ahmet Celal Özsoy
HDHüseyin Avni Demir
Hüseyin Avni Demir
IHİzzettin Hür
İzzettin Hür
ATAhmet Ali Top
Ahmet Ali Top